Cell Death Recombinant Proteins

Human BID Recombinant Protein (RPES3852)

(No reviews yet) Write a Review
SKU:
RPES3852
Product Type:
Recombinant Protein
Species:
Human
Research Area:
Cell Death

Description

system_update_altDatasheet

Human BID Recombinant Protein

The BID protein, also known as BH3-Interacting Domain Death Agonist (BID), belongs to the Bcl-2 protein family and regulates outer mitochondrial membrane permeability. BID is a pro-apoptotic protein that causes cytochrome c to be released from the mitochondria intermembrane space into the cytosol. The interaction between the BID and BAK causes altered mitochondrial membrane permeability. The BID is made up of the BH3 domain, which is required for its interactions with the Bcl-2 family proteins and for pro-death function. Caspases; calpains; Granzyme B and cathepsins are all capable of cleaving Bid. It is a critical aspect of the intrinsic death pathway, which amplifies caspase-dependent and -independent execution of neuronal apoptosis. The inhibition of BID with pharmacological agents has shown promise as a therapeutic strategy in neurological disorders that feature programmed cell death, and it may also aid in the treatment of acute renal failure caused by ischemia-reperfusion. BID is a critical participant in the cell cycle arrest/DNA repair machinery's (ATM) regulation; therefore, it is an ideal candidate to integrate genotoxic stress responses and apoptotic cell death. BID is a novel pro-apoptosis Bcl-2 family protein that activates caspase 8 in response to Fas/TNF-R1 death receptor stimuli. The deletion of BID has been found to protect against liver carcinogenesis; however, this genetic change encourages myeloid cell tumorigenesis. It's possible that this is linked to BID's function of encouraging cell cycle progression through S phase. BID could be also involved in the maintenance of genomic stability by engaging at mitosis checkpoint. Human BID Recombinant Protein is a highly pure recombinant protein developed by Assay Genie for use in a range of applications.

View AllClose

0 Reviews

View AllClose